


11-22-06

1FW

Express Mail Label No.: EV 869861430 US
Date of Deposit: November 20, 2006

Attorney Docket No.: 27374-006 CIP



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Goldstein et al.
SERIAL NUMBER: 10/715,776 EXAMINER : J. R. Samala
FILING DATE: November 18, 2003 ART UNIT : 1618
FOR: OCULAR DIAGNOSIS OF ALZHEIMER'S DISEASE

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (1 page), in duplicate;
3. Copies of Cited Reference B2-B3; C97; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 27374-006 CIP. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Ingrid A. Beattie, Reg. No. 42,306

Christina K. Stock, Reg. No. 45,899

Attorney(s) for Applicants

c/o MINTZ, LEVIN


Address all written correspondence to

Customer no.: 30623

Tel: (617) 542-6000

Fax: (617) 542-2241

Date: November 20, 2006



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Goldstein et al.
SERIAL NUMBER: 10/715,776 EXAMINER : J. R. Samala
FILING DATE: November 18, 2003 ART UNIT : 1618
FOR: OCULAR DIAGNOSIS OF ALZHEIMER'S DISEASE

MAIL STOP AMENDMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.


By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANT: Goldstein et al.
U.S.S.N.: 10/715,776

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 27374-006 CIP.

Respectfully submitted,



Ingrid A. Beattie, Reg. No. 42,306

Christina K. Stock, Reg. No. 45,899

Attorney(s) for Applicants

c/o MINTZ, LEVIN

Address all written correspondence to


Customer no.: 30623

Tel: (617) 542-6000

Fax: (617) 542-2241

Date: November 20, 2006

TRA 1999606v1



Express Mail No.: EV 859861430 US
Date of Deposit: November 20, 2006

Page 1 of 1
Attorney Docket No.: 27374-006 CIP

Please type a plus sign (+) in this box



PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number		10/715,776	
				Filing Date		November 18, 2003	
				First Named Inventor		Goldstein	
				Group Art Unit		1618	
				Examiner Name		J. R. Samala	
				Attorney Docket Number		27374-006 CIP	
U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B2	CA	2,272,320	Turner et al.	05/28/98		
	B3	CA	2,301,142	Glabe et al.	02/25/99		
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
	C97	Frederikse et al., "Oxidative stress increase production of β -amyloid precursor protein and β -amyloid ($A\beta$) in mammalian lenses, and $A\beta$ has toxic effects on lens epithelial cells", <i>J. Biol. Chem.</i> , 271(17):10169-10174 (1996)					

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.